(Q34735112)

4 August 2017

1 reference

title

The expanding role of fluoroquinolones. (English)

1 reference

4 August 2017

Anthony J Schaeffer

1

1 reference

PubMed ID

12113871

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

American Journal of Medicine

4 August 2017

1 reference

4 August 2017

113 Suppl 1A

1 reference

4 August 2017

45S-54S

1 reference

Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

The safety profile of the fluoroquinolones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Activity of levofloxacin and ciprofloxacin against urinary pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Fluoroquinolones in paediatrics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Safety of oral ciprofloxacin. An update based on clinical trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Hypersensitivity and anaphylactoid reactions to ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Possible interaction of ciprofloxacin with cyclosporin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Gatifloxacin, an advanced 8-methoxy fluoroquinolone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Bactericidal activity of gatifloxacin (AM-1155) against Pseudomonas aeruginosa and Enterococcus faecalis in an in vitro bladder model simulating human urinary concentrations after oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Fluoroquinolone toxicity profiles: a review focusing on newer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Economic aspects of antibacterial adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Enoxacin relieves symptoms of recurrent urinary infections more rapidly than cefuroxime axetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Prevention of subsequent urinary tract infections in women by the use of anti-adherence antimicrobial agents: a double-blind comparison of enoxacin with co-trimoxazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Tolerability of fluoroquinolone antibiotics. Past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Review of norfloxacin in lower urinary tract infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Central nervous system toxicity of quinolones: human and animal findings

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Survey on antibiotic usage in the treatment of urinary tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

Levofloxacin and warfarin interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901059-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(02)01059-8

1 reference

4 August 2017

1 reference

PubMed ID

12113871